Targeting the energy production process in pancreatic cancer cells, which relies on an enzyme called cytidine deaminase, could make these cells more vulnerablen ligase TRIP12 is required for pancreatic acinar cell plasticity and the development of pancreatic cancer.

3 Sep 2024 | Discover home page, Discover ImPact

Targeting the energy production process in pancreatic cancer cells, which relies on an enzyme called cytidine deaminase, could make these cells more vulnerable Pancreatic cancer, cytidine deaminase, energetic metabolism, resistance to treatment. Pierre Cordelier...

The E3 ubiquitin ligase TRIP12 is required for pancreatic acinar cell plasticity and the development of pancreatic cancer.

18 Jul 2024 | Discover home page, Discover ImPact

The E3 ubiquitin ligase TRIP12 is required for pancreatic acinar cell plasticity and the development of pancreatic cancer. thyroid hormone receptor interacting protein 12; pancreatic cancer; preneoplastic lesions; acinar-to-ductal metaplasia; E3 ubiquitin ligase...

An oncolytic virus with strong appetence for the most aggressive type of pancreatic cancer cells

11 Apr 2024 | Discover home page, Discover ImPact

An oncolytic virus with strong appetence for the most aggressive type of pancreatic cancer cells Oncolytic virus, pancreatic cancer, precision medicine Pierre Cordelier – Team ImPact – Therapeutic innovation in pancreatic cancer The Minute virus of mice...

Cytidine deaminase confers resistance to DNA-damaging drugs

2 Feb 2024 | Discover home page, Discover ImPact

Cytidine deaminase confers resistance to DNA-damaging drugs Pancreatic cancer, cytidine deaminase, replication stress, resistance to treatment Pierre Cordelier – Team ImPact – Therapeutic innovation in pancreatic cancer Cytidine deaminase (CDA) plays a...

Focus research 2022 ImPact team

2 Oct 2023 | Discover ImPact

Focus research 2022 ImPact team Pancreatic tumors are notorious for their resistance to immunotherapies. In this context, the ImPACT team has been investigating the therapeutic potential of Toll-like receptor (TLR) agonist molecules, which are expressed in tumors, and...

Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer

27 Mar 2023 | Discover home page, Discover ImPact

Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer Pancreatic cancer, non-viral gene therapy, resistance to treatment, chemotherapy, preclinical regulatory experiments. Pierre Cordelier Team ImPact- Therapeutic innovation in...